JW Pharmaceutical highlighted the therapeutic potential of DDC-02 in multiple neurodevelopmental disorder models at WODC USA ...
TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company ...
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma. In this GEN webinar, ...
HKeyBio, a preclinical contract research organization focused on autoimmune and allergic diseases, today announced the launch of HKEY-ExE™ 1.0, an EoE&EgE Evaluation Framework for eosinophilic ...
As drug developers pursue increasingly complex therapies, traditional bioanalytical approaches are being put to the test. How ...
Antibacterial resistance is a global challenge that requires a coordinated international response. The current clinical pipeline largely consists of derivatives of established antibiotic classes, ...
This Brush Up is sponsored by MilliporeSigma. Learn more about therapeutic synthesis pathways. Drug development is a process that spans many years, from the initial phase of identifying potential drug ...
Data presented at WODC USA 2026 Support Potential Application Across Multiple Indications, Including Pitt-Hopkins Syndrome, Fragile X Syndrome, and Rett Syndrome Restoration of Cognitive and ...
JW Pharmaceutical (KRX:001060) presented preclinical findings and its global development strategy for DDC-02, a therapeutic candidate for rare neurodevelopmental disorders, at the World Orphan Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results